TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29273269

Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once daily on alternate days on days 7-25)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Vancomycin (125 mg oral capsules, four times daily on days 1-10)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin
Number of subjects: 364

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 364
Study: 26649741

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2000 mg and Avibactam 500 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24739875

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 32

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 32
Study: 23169194

Group type: EXPERIMENTAL
Intervention: Verified prescription using probe‐microphone measurement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Initial-fit approach
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Verified prescription
Number of subjects: 22
Study: 20089954

Group type: EXPERIMENTAL
Intervention: Oral fingolimod 1.25 mg
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Oral fingolimod 0.5 mg
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Intramuscular interferon beta-1a
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Progression of disability
Number of subjects: 1292
Study: 18931224

Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (30,000 IU IV over 4 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-dose antithrombin
Number of subjects: 81
Study: 16128153

Group type: EXPERIMENTAL
Intervention: Old/new ERP effect for words
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Topography differences in activation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Semantic versus non-semantic processing
Number of subjects: 74
Study: 11495875

Group type: EXPERIMENTAL
Intervention: 3 mg of intrathecal ropivacaine (group R)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 mg ropivacaine with 10 microg of sufentanil (group RS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 9759744

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily for 1 week)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control treatment (omeprazole with placebo antibiotics)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 285
Study: 8166097

Group type: EXPERIMENTAL
Intervention: Wire fixation (WF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rigid fixation (RIF)
Number of subjects: 20
Study: 3139337

Group type: EXPERIMENTAL
Intervention: 500 micrograms iodide/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1500 micrograms iodide/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4500 micrograms iodide/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1500 micrograms iodide/day and 4500 micrograms iodide/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 30
Study: 30630361

Group type: COMPARATOR
Intervention: Placebo + Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 0
Study: 28473006

Group type: EXPERIMENTAL
Intervention: Watermemories Swimming Club aquatic exercise program (12 weeks, twice weekly)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 25979100

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Attention control condition (HF self-management with sleep hygiene)
Number of subjects: 29
Study: 23580069

Group type: EXPERIMENTAL
Intervention: Boost arm
Number of subjects: 688

Group type: COMPARATOR
Intervention: No boost arm
Number of subjects: 688
Study: 20926529

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.64 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19365011

Group type: EXPERIMENTAL
Intervention: 0.3 mg pegaptanib sodium
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 1 mg pegaptanib sodium
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 65
Study: 16919571

Group type: EXPERIMENTAL
Intervention: 64-slice MSCT
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D echocardiography
Number of subjects: 40
Study: 15589022

Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential shock waveform at 200 J for patients weighing <90 kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential shock waveform at 360 J for patients weighing >=90 kg
Number of subjects: 120
Study: 11264907

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 24
Study: 9146855

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (600 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7711007

Group type: EXPERIMENTAL
Intervention: Glucose (100 g in 400 ml) administered 30 min before tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (equal volume to glucose) administered 30 min before tests
Number of subjects: 0
Study: 31780018

Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST)
Number of subjects: 58
Study: 30538005

Group type: EXPERIMENTAL
Intervention: rs805305 SNP of DDAH2
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Peak ADMA concentration
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Reduced DDAH activity (elevated ADMA:SDMA ratio)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: G:G genotype
Number of subjects: 286
Study: 26683126

Group type: EXPERIMENTAL
Intervention: Intraoperative application of Platelet-Rich Plasma (PRP)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no PRP/PPP)
Number of subjects: 250
Study: 25439692

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once-daily
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study: 23044290

Group type: EXPERIMENTAL
Intervention: Anisodamine infusion at a rate of 0.2 µg×kg(‐1)×min(‐1) from 12 hours before to 12 hours after coronary angiography or angioplasty
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sodium chloride infusion (control group)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Anisodamine infusion
Number of subjects: 260
Study: 19665908

Group type: EXPERIMENTAL
Intervention: Positive mood with AMAC stop rule instruction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Negative mood with AMAC stop rule instruction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Positive mood with FLDC stop rule instruction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Negative mood with FLDC stop rule instruction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AMAC stop rule instruction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: FLDC stop rule instruction
Number of subjects: 62
Study: 18839224

Group type: EXPERIMENTAL
Intervention: MESNA (Uromixetan MESNA, 50 mg/ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 30
Study: 16644299

Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated OI patients
Number of subjects: 14
Study: 14500050

Group type: EXPERIMENTAL
Intervention: Treatment A (initially allocated in a 1:1 ratio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B (initially allocated in a 1:1 ratio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group sequential design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonadaptive design
Number of subjects: 0
Study: 10813582

Group type: EXPERIMENTAL
Intervention: Breast milk from allergic mothers
Number of subjects: 48

Group type: COMPARATOR
Intervention: Breast milk from nonallergic mothers
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Breast milk samples (colostrum and mature milk)
Number of subjects: 48
Study: 8800482

Group type: EXPERIMENTAL
Intervention: 0.6% monosodium glutamate (MSG) added to vegetable and starch dishes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no MSG)
Number of subjects: 31
Study: 1310103

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (EP) for 12 weeks
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and vincristine (CAV) for 18 weeks
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Alternation of CAV and EP (CAV/EP) for 18 weeks
Number of subjects: 437
Study: 6701925

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and radiotherapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Reduced-dose irradiation and subsequent simultaneous combination of polychemotherapy and irradiation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Both groups of randomization
Number of subjects: 108
Study: 31479804

Group type: EXPERIMENTAL
Intervention: Laser-assisted MAL-PDT associated with acoustic pressure wave ultrasound with 1-hour incubation time
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional MAL-PDT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Laser-assisted MAL-PDT associated with acoustic pressure wave ultrasound
Number of subjects: 15
Study: 29266675

Group type: EXPERIMENTAL
Intervention: E5/S100
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: E15/S100
Number of subjects: 1233

Group type: COMPARATOR
Intervention: E5
Number of subjects: 1233

Group type: COMPARATOR
Intervention: E15
Number of subjects: 1233

Group type: COMPARATOR
Intervention: S100
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: E5/S100 and E15/S100
Number of subjects: 1233
Study: 26850706

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 763
Study: 24463426

Group type: EXPERIMENTAL
Intervention: Artistic gymnasts
Number of subjects: 24

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Older participants (14-20 years)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Younger participants (7-13 years)
Number of subjects: 24
Study: 22329861

Group type: EXPERIMENTAL
Intervention: Surgical debridement (SD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-surgical debridement (NSD)
Number of subjects: 21
Study: 20657150

Group type: EXPERIMENTAL
Intervention: Saliva
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 17170047

Group type: EXPERIMENTAL
Intervention: Skilled cycling training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-skilled cycling training
Number of subjects: 23
Study: 15296815

Group type: EXPERIMENTAL
Intervention: Ordinary least squares (OLS) estimator without adjusting for measurement error
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adjustment for measurement error
Number of subjects: 30
Study: 12474066

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 mL daily for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 50
Study: 9841956

Group type: EXPERIMENTAL
Intervention: Sodium citrate solution (0.3 g x kg‐1 body mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7806684

Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Haloperidol (all doses)
Number of subjects: 22
Study: 2760092

Group type: EXPERIMENTAL
Intervention: Repair and augmentation of the anterior cruciate ligament with a strip of the iliotibial band
Number of subjects: 111

Group type: COMPARATOR
Intervention: Simple repair of all injured structures
Number of subjects: 111

Group type: COMPARATOR
Intervention: Repair of all injured structures except the anterior cruciate ligament
Number of subjects: 111
Study: 67592

Group type: EXPERIMENTAL
Intervention: Synthetic salmon thyrocalcitonin 80 u/day for three months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30547421

Group type: EXPERIMENTAL
Intervention: Parent‐directed mask exposure/shaping practice at least once on the day of surgery (Group 2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No exposure prior to induction (Group 3)
Number of subjects: 110
Study: 28505233

Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone (DEX), ondansetron (OND), and droperidol (DRO) (Group B)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Combination of dexamethasone (DEX) and ondansetron (OND) (Group A)
Number of subjects: 315
Study: 24903578

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Music intervention program
Number of subjects: 24
Study: 23972577

Group type: EXPERIMENTAL
Intervention: FD‐APAP 1000 mg
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: FD‐APAP 500 mg
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: APAP 650 mg
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 22433304

Group type: EXPERIMENTAL
Intervention: ETV 1.0 mg/d monotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: ETV + ADV 10 mg/d
Number of subjects: 40
Study: 19454403

Group type: EXPERIMENTAL
Intervention: SGS (structured diabetes teaching and treatment programme)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard DTTP
Number of subjects: 155
Study: 17014428

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus acidophilus LAVRI‐A1; Probiomics)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo (maltodextrin alone)
Number of subjects: 231
Study: 12601511

Group type: EXPERIMENTAL
Intervention: Pelvicol( trademark ) implant
Number of subjects: 142

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 142
Study: 10990104

Group type: EXPERIMENTAL
Intervention: Dopamine (4 microg/kg per minute)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8724378

Group type: EXPERIMENTAL
Intervention: Hypertonic glucose solution (Group I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glucose and 20% long-chain triacylglycerides emulsion (Group II)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20% emulsion of a mixture of medium-chain and long-chain triacylglycerides (Group III)
Number of subjects: 21
Study: 1524959

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3927062

Group type: EXPERIMENTAL
Intervention: Group Ia - Glucose alone as energy source
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group Ib - Mixture of glucose and fructose
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group II - Specially formulated amino acid solution with glucose and fructose
Number of subjects: 61
Study: 31792324

Group type: EXPERIMENTAL
Intervention: Genetic methods (microsatellite loci)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Network analysis, causal modelling, multiple matrix regression with randomization
Number of subjects: 11
Study: 29317275

Group type: EXPERIMENTAL
Intervention: Dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (DIS1 group)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Dose increase to 10 mg/kg based on clinical symptoms alone (control group)
Number of subjects: 122
Study: 28137501

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 1620

Group type: COMPARATOR
Intervention: VI 25 μg
Number of subjects: 1620
Study: 25511449

Group type: EXPERIMENTAL
Intervention: POLD technique (manual oscillatory therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 30
Study: 23443345

Group type: EXPERIMENTAL
Intervention: Transvaginal electrical stimulation with surface-EMG biofeedback (TVES + sEMG)
Number of subjects: 102
Study: 21627406

Group type: EXPERIMENTAL
Intervention: High-protein diet (30% protein, 40% carbohydrate, 30% lipid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal-protein diet (15% protein, 55% carbohydrate, 30% lipid)
Number of subjects: 40
Study: 19141980

Group type: EXPERIMENTAL
Intervention: Group A (rabeprazole, clarithromycin, and furazolidone)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Group B (ranitidine bismuth citrate, clarithromycin, and furazolidone)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Group C (rabeprazole, amoxicillin, and furazolidone)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Group D (ranitidine bismuth citrate, amoxicillin, and furazolidone)
Number of subjects: 307
Study: 16185755

Group type: EXPERIMENTAL
Intervention: MVAC (methotrexate 30 mg/m2 IV days 1, 15, and 22, vinblastine 3 mg/m2 IV days 2, 15, and 22, doxorubicin 30 mg/m2 IV day 2, cisplatin 70 mg/m2 day 2 of a 4-week cycle)
Number of subjects: 28

Group type: COMPARATOR
Intervention: AC (doxorubicin 30 mg/m2 + cisplatin 70 mg/m2 IV q 4 weeks)
Number of subjects: 28
Study: 12943180

Group type: EXPERIMENTAL
Intervention: Qigong (Shuxinpingxuegong)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 11215835

Group type: EXPERIMENTAL
Intervention: 50/50 titration schedule (initial dosage 50 mg/d increased in 50 mg/d increments at weekly intervals)
Number of subjects: 188

Group type: COMPARATOR
Intervention: 100/200 titration schedule (initial dosage 100 mg/d increased by 100-200 mg/d at weekly intervals)
Number of subjects: 188
Study: 9034229

Group type: EXPERIMENTAL
Intervention: CaP/P tablet formulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CaP/GG tablet formulation
Number of subjects: 10
Study: 8515293

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g i.v. single dose)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Piperacillin (2 g i.v. single dose)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Both cefotetan and piperacillin
Number of subjects: 561
Study: 3027841

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for five days (women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sexual partners of women)
Number of subjects: 0
Study: 31044654

Group type: EXPERIMENTAL
Intervention: Art therapy (AT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine medical treatment (Control Group)
Number of subjects: 62
Study: 29500079

Group type: EXPERIMENTAL
Intervention: Intentional learning (explicit instructions)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard learning (no explicit instructions)
Number of subjects: 48
Study: 25362247

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid injections combined with a single local injection of corticosteroid-lidocaine (Group 2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intraarticular hyaluronic acid injections only (Group 1)
Number of subjects: 70
Study: 24639149

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two doses of 510 mg 5 ± 3 days apart)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Iron sucrose (five doses of 200 mg on five nonconsecutive days over 14 days)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 605

Group type: COMPARATOR
Intervention: Iron sucrose
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Ferumoxytol and Iron sucrose
Number of subjects: 605
Study: 23967637

Group type: EXPERIMENTAL
Intervention: Staging treatment group (acupuncture at tendon points, electric thermal needling, small needle-knife therapy, bleeding method, electric thermal therapy with thick silver needles)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) group (EA applied at Liangqiu (ST 34), Xuehai (SP 10), Yanglingquan (GB 34))
Number of subjects: 180
Study: 21210610

Group type: EXPERIMENTAL
Intervention: Simulation experience
Number of subjects: 63

Group type: COMPARATOR
Intervention: Traditional skills laboratory method
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 18005487

Group type: EXPERIMENTAL
Intervention: Food advertisements
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-food adverts
Number of subjects: 59
Study: 17236639

Group type: EXPERIMENTAL
Intervention: Intraoperative spinal analgesia (IT group: bupivacaine or clonidine 300 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative epidural analgesia (EPID group: bupivacaine, sufentanil, and clonidine 1 microg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia alone (GA group)
Number of subjects: 0
Study: 12482554

Group type: COMPARATOR
Intervention: DHA (4 g/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: EPA (4 g/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Placebo (olive oil)
Number of subjects: 59
Study: 10839588

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Protease Inhibitor (PI)
Number of subjects: 138
Study: 9316528

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg/day
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Enalapril 20 mg/day
Number of subjects: 116
Study: 8403674

Group type: EXPERIMENTAL
Intervention: Local antibiotics (Septopal) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antibiotics or combined treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral antibiotics
Number of subjects: 0
Study: 2883060

Group type: EXPERIMENTAL
Intervention: 25 micrograms SMS 201-995 twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25 micrograms SMS 201-995
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31584341

Group type: EXPERIMENTAL
Intervention: Treatment of distal radial fractures
Number of subjects: 0